Çocukluk Çağında Akut Lenfoblastik Lösemi

Yöntem, Ahmet; Bayram, İbrahim

doi:10.17827/aktd.397762

Cited by 2 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Especially, under 3 months has the worst prognosis, while the prognosis is better in the range of 6-12 months. 1,4 The best prognosis is seen between the ages of 2-6 in all age groups. 9 In our study, the median age at the time of diagnosis was 4.5 years and had similar results with studies in Germany and Korea.…”

Section: Discussionmentioning

confidence: 97%

“…Therefore, they may be more susceptible to chemotherapeutic interventions. 1,2,15,16 In a study investigating the effect of Hb level on prognosis, complete remission rates were reported as 63% when Hb level was <8 g/dl, 70% between 10-12 g/dl and 60% when >12 g/dl. It has been stated that the level does not affect the life span.…”

Section: Discussionmentioning

confidence: 99%

“…Acute lymphoblastic leukemia (ALL) is five times more common in children under the age of 15 than acute myeloblastic leukemia (AML) and the incidence of ALL in 0-14 years of age is 41.4/1.000.000 in our country. 1,2 While the response and survival rate to ALL treatment was about 10% in the 1960s, remission can be achieved at a rate of 80-90% with current treatment protocols arranged according to the biological characteristics of leukemia cells. 1 In parallel with the advances in diagnosis and treatment, some clinical and laboratory findings have been found to be effective on prognosis and treatment according to risk has come to the fore.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 While the response and survival rate to ALL treatment was about 10% in the 1960s, remission can be achieved at a rate of 80-90% with current treatment protocols arranged according to the biological characteristics of leukemia cells. 1 In parallel with the advances in diagnosis and treatment, some clinical and laboratory findings have been found to be effective on prognosis and treatment according to risk has come to the fore.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Value of Myeloid Marker Positivity and its Association with Prognostic Factors in Pediatric Acute Lymphoblastic Leukemia

Topal¹,

Semerci²,

Çiçek³

et al. 2021

Trends in Pediatrics

View full text Add to dashboard Cite

Objective:The aim of this study is to investigate the effect of myeloid marker positivity on prognosis and its relationship with classical prognostic factors in acute lymphoblastic leukemia (ALL). Methods: Cases who were newly diagnosed with ALL, followed up in our hospital were included. CD13, CD14 and CD33 were used as myeloid markers by immunophenotyping with flow cytometry in the bone marrow samples. Any parameter higher than 20% was accepted as positive.Modified BFM-2000 protocol was used in treatment and ALL-BFM-95 residual protocols were used in relapses. Risk groups were determined according to the Trall-BFM-2000 protocol. Clinical, laboratory and demographic characteristics of participants such as age, gender, leukocyte count at the time of diagnosis, were all recorded. Patients were divided into three groups according to myeloid markers; those with negative myeloid markers (Group-I), positive one of the myeloid markers (Group-II), those with multiple positive myeloid markers (Group-III). For overall survival, death only was accepted, relapse or death were taken as failure for event free survival (EFS). Results: A total of 96 ALL cases were included. 44 of the patients were male and 52 were female. Their ages were between 10-204 months and median value was 4.5 years. Nine patients were T-ALL (9.4%), one had biphenotype ALL (1%), and 86 had B precursor cell ALL (89.6%). Group-I had 47 patients. One or more myeloid markers were found to be positive in 49 patients (51.1%). While 42 of them consisted group-II, group-III had 7 patients. The EFS distribution for all patients was between 43,16-52 months, with a median of 45.58 months. There was no difference between the groups in terms of EFS (p 0.871). Conclusion:This study revealed that myeloid markers had no effect on prognosis. When compared with parameters with prognostic significance, no difference was found except between FAB morphology and myeloid markers. Therefore, studies involving more patients are needed to obtain more precise information on the subject.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Value of Myeloid Marker Positivity and its Association with Prognostic Factors in Pediatric Acute Lymphoblastic Leukemia

Topal¹,

Semerci²,

Çiçek³

et al. 2021

Trends in Pediatrics

View full text Add to dashboard Cite

show abstract

“…This formation which can be seen in all age groups constitutes %25-%30 of childhood cancers. About %97 of leukaemias evaluated on this scale are acute leukaemias (Yöntem and Bayram 2018). Acute leukaemias which are frequently seen in childhood leukaemias compared to adults are haematological disorders that occur in the differentiation process of myeloid and lymphoid cells.…”

Section: Introductionmentioning

confidence: 99%

Mikrodizi Veri Kümesi Üzerinde Doğadan İlham Alan Optimizasyon ile Birleştirilen Uyarlanabilir Ağ Tabanlı Bulanık Çıkarım Sistemi Kullanılarak T-ALL, B-ALL ve T-LL Malignitelerinin Sınıflandırılması

AKALIN,

YUMUŞAK

2023

Afyon Kocatepe University Journal of Sciences and Engineering

View full text Add to dashboard Cite

Leukemia is the formation of cancer with different characteristic findings. According to the progress type of disease in the body is called acute or chronic. Acute leukemias are characterized by the presence of blast cells that proliferate uncontrollably in the bone marrow and then go into the blood and tissues. Determination of T/B or non T/B cell class is important in the immunophenotypic evaluation related to subtypes of blast cells. Because the diagnosis and treatment processes of B-ALL, T-ALL and T-LL subtypes, which are composed of B and T cell lines, are different. Therefore, correct diagnosis is vital. In this study, the molecular diagnosis was provided for the accurate detection of T-ALL, B-ALL and T-LL subtypes through microarray datasets. But, microarray datasets have a multidimensional structure. Because it contains information related to the disease as well as information not related to the disease. This situation also affects the training situation and computational cost of the model. For this, the whale optimization algorithm was used in the first stage of the study. Thus, related genes were selected from the data set. Secondly, the selected potential genes were given as input to the ANFIS structure. Then, in order to improve the inference power, parameter optimization related to the membership function of the ANFIS structure was provided with ABC and PSO optimization algorithms. Finally, the predictions obtained from the ANFIS, ANFIS+ABC, and ANFIS+PSO methods for each sample were classified using the logistic regression algorithm and, an accuracy rate of 86.6% was obtained.

show abstract

Çocukluk Çağında Akut Lenfoblastik Lösemi

Cited by 2 publications

References 52 publications

Prognostic Value of Myeloid Marker Positivity and its Association with Prognostic Factors in Pediatric Acute Lymphoblastic Leukemia

Prognostic Value of Myeloid Marker Positivity and its Association with Prognostic Factors in Pediatric Acute Lymphoblastic Leukemia

Mikrodizi Veri Kümesi Üzerinde Doğadan İlham Alan Optimizasyon ile Birleştirilen Uyarlanabilir Ağ Tabanlı Bulanık Çıkarım Sistemi Kullanılarak T-ALL, B-ALL ve T-LL Malignitelerinin Sınıflandırılması

Contact Info

Product

Resources

About